Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

8

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

A673

8

DNA topoisomerase II

8

DNA topoisomerase II alpha

8

HepG2

8

Human ovarian cancer cell line

8

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

8

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1974

8

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

AIDS-related Kaposi’s sarcoma

8

Glioblastoma

8

Kaposi’s sarcoma

8

Locally advanced or unresectable soft tissue sarcoma

8

Metastatic non-small cell lung cancer

8

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

8

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

8

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

The Regents of The University of Colorado

8

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

9

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

9

FDA UNII

9

PUBCHEM

9

NCI_THESAURUS

8

DRUG BANK

7

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTINEOPLASTIC AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Anthracyclines and related substances

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

7

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 9 of 9 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

DOXORUBICIN

80168379AG

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

DNA topoisomerase II

Conditions:

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...

er agent, doxorubicin, into the tumor. Currently, in late-stage clinical trials, Aldoxorubicin appears to overcome the key limitations of doxorubicin, including cumulative dose restrictions. Aldoxorubicin utilizes an acid-sensitive linker that selectively binds to albumin, which may allow the cytotoxic payload to preferentially accumulate in the tumor and potentially spare the surrounding healthy tissue. This mechanism leverages the tumor's low pH environment and accompanying dependency upon circulating albumin to fuel growth, to enable the delivery of multifold times the standard dosing of doxorubicin. The preferential uptake of Aldoxorubicin by tumor tissue and the acid sensitive release of doxorubicin allow for Aldoxorubicin to be a very promising anticancer agent. In phase I and II trials, Aldoxorubicin demonstrates superior efficacy over doxorubicin. Although the studies were not powered for OS, Aldoxorubicin shows improved PFS and tumor response in comparison to doxorubicin. The safety profile was also comparable to that of doxorubicin. Similarly, results from the recent phase III study showed a benefit in PFS in the leiomyosarcoma subtypes.

2,5-DIHYDROXYBENZALDEHYDE

0Q83HDS90W

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

AVA-6000

7XPB9B6MUA

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

DNA topoisomerase II

Conditions:

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...

er agent, doxorubicin, into the tumor. Currently, in late-stage clinical trials, Aldoxorubicin appears to overcome the key limitations of doxorubicin, including cumulative dose restrictions. Aldoxorubicin utilizes an acid-sensitive linker that selectively binds to albumin, which may allow the cytotoxic payload to preferentially accumulate in the tumor and potentially spare the surrounding healthy tissue. This mechanism leverages the tumor's low pH environment and accompanying dependency upon circulating albumin to fuel growth, to enable the delivery of multifold times the standard dosing of doxorubicin. The preferential uptake of Aldoxorubicin by tumor tissue and the acid sensitive release of doxorubicin allow for Aldoxorubicin to be a very promising anticancer agent. In phase I and II trials, Aldoxorubicin demonstrates superior efficacy over doxorubicin. Although the studies were not powered for OS, Aldoxorubicin shows improved PFS and tumor response in comparison to doxorubicin. The safety profile was also comparable to that of doxorubicin. Similarly, results from the recent phase III study showed a benefit in PFS in the leiomyosarcoma subtypes.

ZOPTARELIN DOXORUBICIN ACETATE

4IA03SIO30

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

DNA topoisomerase II

Conditions:

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...

er agent, doxorubicin, into the tumor. Currently, in late-stage clinical trials, Aldoxorubicin appears to overcome the key limitations of doxorubicin, including cumulative dose restrictions. Aldoxorubicin utilizes an acid-sensitive linker that selectively binds to albumin, which may allow the cytotoxic payload to preferentially accumulate in the tumor and potentially spare the surrounding healthy tissue. This mechanism leverages the tumor's low pH environment and accompanying dependency upon circulating albumin to fuel growth, to enable the delivery of multifold times the standard dosing of doxorubicin. The preferential uptake of Aldoxorubicin by tumor tissue and the acid sensitive release of doxorubicin allow for Aldoxorubicin to be a very promising anticancer agent. In phase I and II trials, Aldoxorubicin demonstrates superior efficacy over doxorubicin. Although the studies were not powered for OS, Aldoxorubicin shows improved PFS and tumor response in comparison to doxorubicin. The safety profile was also comparable to that of doxorubicin. Similarly, results from the recent phase III study showed a benefit in PFS in the leiomyosarcoma subtypes.

DOXORUBICIN CITRATE

AJQ2ZNG2WL

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

DNA topoisomerase II

Conditions:

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...

er agent, doxorubicin, into the tumor. Currently, in late-stage clinical trials, Aldoxorubicin appears to overcome the key limitations of doxorubicin, including cumulative dose restrictions. Aldoxorubicin utilizes an acid-sensitive linker that selectively binds to albumin, which may allow the cytotoxic payload to preferentially accumulate in the tumor and potentially spare the surrounding healthy tissue. This mechanism leverages the tumor's low pH environment and accompanying dependency upon circulating albumin to fuel growth, to enable the delivery of multifold times the standard dosing of doxorubicin. The preferential uptake of Aldoxorubicin by tumor tissue and the acid sensitive release of doxorubicin allow for Aldoxorubicin to be a very promising anticancer agent. In phase I and II trials, Aldoxorubicin demonstrates superior efficacy over doxorubicin. Although the studies were not powered for OS, Aldoxorubicin shows improved PFS and tumor response in comparison to doxorubicin. The safety profile was also comparable to that of doxorubicin. Similarly, results from the recent phase III study showed a benefit in PFS in the leiomyosarcoma subtypes.

ALDOXORUBICIN HYDROCHLORIDE

S098K6HGD9

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

DNA topoisomerase II

Conditions:

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...

er agent, doxorubicin, into the tumor. Currently, in late-stage clinical trials, Aldoxorubicin appears to overcome the key limitations of doxorubicin, including cumulative dose restrictions. Aldoxorubicin utilizes an acid-sensitive linker that selectively binds to albumin, which may allow the cytotoxic payload to preferentially accumulate in the tumor and potentially spare the surrounding healthy tissue. This mechanism leverages the tumor's low pH environment and accompanying dependency upon circulating albumin to fuel growth, to enable the delivery of multifold times the standard dosing of doxorubicin. The preferential uptake of Aldoxorubicin by tumor tissue and the acid sensitive release of doxorubicin allow for Aldoxorubicin to be a very promising anticancer agent. In phase I and II trials, Aldoxorubicin demonstrates superior efficacy over doxorubicin. Although the studies were not powered for OS, Aldoxorubicin shows improved PFS and tumor response in comparison to doxorubicin. The safety profile was also comparable to that of doxorubicin. Similarly, results from the recent phase III study showed a benefit in PFS in the leiomyosarcoma subtypes.

ALDOXORUBICIN

C28MV4IM0B

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

DNA topoisomerase II

Conditions:

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...

er agent, doxorubicin, into the tumor. Currently, in late-stage clinical trials, Aldoxorubicin appears to overcome the key limitations of doxorubicin, including cumulative dose restrictions. Aldoxorubicin utilizes an acid-sensitive linker that selectively binds to albumin, which may allow the cytotoxic payload to preferentially accumulate in the tumor and potentially spare the surrounding healthy tissue. This mechanism leverages the tumor's low pH environment and accompanying dependency upon circulating albumin to fuel growth, to enable the delivery of multifold times the standard dosing of doxorubicin. The preferential uptake of Aldoxorubicin by tumor tissue and the acid sensitive release of doxorubicin allow for Aldoxorubicin to be a very promising anticancer agent. In phase I and II trials, Aldoxorubicin demonstrates superior efficacy over doxorubicin. Although the studies were not powered for OS, Aldoxorubicin shows improved PFS and tumor response in comparison to doxorubicin. The safety profile was also comparable to that of doxorubicin. Similarly, results from the recent phase III study showed a benefit in PFS in the leiomyosarcoma subtypes.

ZOPTARELIN DOXORUBICIN

27844X2J29

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

DNA topoisomerase II

Conditions:

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...

er agent, doxorubicin, into the tumor. Currently, in late-stage clinical trials, Aldoxorubicin appears to overcome the key limitations of doxorubicin, including cumulative dose restrictions. Aldoxorubicin utilizes an acid-sensitive linker that selectively binds to albumin, which may allow the cytotoxic payload to preferentially accumulate in the tumor and potentially spare the surrounding healthy tissue. This mechanism leverages the tumor's low pH environment and accompanying dependency upon circulating albumin to fuel growth, to enable the delivery of multifold times the standard dosing of doxorubicin. The preferential uptake of Aldoxorubicin by tumor tissue and the acid sensitive release of doxorubicin allow for Aldoxorubicin to be a very promising anticancer agent. In phase I and II trials, Aldoxorubicin demonstrates superior efficacy over doxorubicin. Although the studies were not powered for OS, Aldoxorubicin shows improved PFS and tumor response in comparison to doxorubicin. The safety profile was also comparable to that of doxorubicin. Similarly, results from the recent phase III study showed a benefit in PFS in the leiomyosarcoma subtypes.

DOXORUBICIN HYDROCHLORIDE

82F2G7BL4E

Export Data
Search for Structure

Status:

US Approved Rx (2022)

First approved in 1974

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

Human ovarian cancer cell line

DNA topoisomerase II alpha

DNA topoisomerase II

Conditions:

AIDS-related Kaposi’s sarcoma

Multiple myeloma

Locally advanced or unresectable soft tissue sarcoma

Kaposi’s sarcoma

Metastatic non-small cell lung cancer

Pancreatic ductal adenocarcinoma

Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...

er agent, doxorubicin, into the tumor. Currently, in late-stage clinical trials, Aldoxorubicin appears to overcome the key limitations of doxorubicin, including cumulative dose restrictions. Aldoxorubicin utilizes an acid-sensitive linker that selectively binds to albumin, which may allow the cytotoxic payload to preferentially accumulate in the tumor and potentially spare the surrounding healthy tissue. This mechanism leverages the tumor's low pH environment and accompanying dependency upon circulating albumin to fuel growth, to enable the delivery of multifold times the standard dosing of doxorubicin. The preferential uptake of Aldoxorubicin by tumor tissue and the acid sensitive release of doxorubicin allow for Aldoxorubicin to be a very promising anticancer agent. In phase I and II trials, Aldoxorubicin demonstrates superior efficacy over doxorubicin. Although the studies were not powered for OS, Aldoxorubicin shows improved PFS and tumor response in comparison to doxorubicin. The safety profile was also comparable to that of doxorubicin. Similarly, results from the recent phase III study showed a benefit in PFS in the leiomyosarcoma subtypes.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1